v3.26.1
Segment Information - Summary of significant segment expenses and segment net loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Abstract]              
Canvuparatide direct program expense $ 13,943   $ 8,923   $ 22,049 $ 17,260  
MBX 4291 direct program expense 7,061   2,547   9,009 8,322  
Imapextide direct program expense 1,026   987   1,947 2,793  
Preclinical and other research and development direct expense 1,602   1,641   2,875 2,850  
Research and development overhead expense 7,353   3,626   13,579 8,905  
Other segment items [1] 6,110   1,687   11,153 3,161  
Net loss $ 37,095 $ 23,517 $ 19,411 $ 23,880 $ 60,612 $ 43,291 $ 87,000
[1] Other segment items are primarily comprised of general and administrative expenses and interest and other income.